Drug Profile

KHK 6640

Alternative Names: KHK-6640

Latest Information Update: 25 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator OncoTherapy Science
Developer Kyowa Kirin; OncoTherapy Science
Class Antidementias; Monoclonal antibodies; Peptides
Mechanism of Action Amyloid beta-protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Alzheimer's disease

Most Recent Events

25 Feb 2025 Phase-I/II development is ongoing in Europe (OncoTherapy Science Pipeline, February 2025)
28 Aug 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease in Serbia (IV)
06 Aug 2021 KHK 6640 is still in phase I trials for Alzheimer's disease in Serbia, Sweden, Netherlands, Japan, Finland, Belgium (Kyowa Kirin pipeline, August 2021)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com